Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
Public ClinicalTrials.gov record NCT00895583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Planned Transition To Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy In Renal Allograft Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
Study identification
- NCT ID
- NCT00895583
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 254 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Aug 2013 (Actual)
- Completion
- Aug 2013 (Actual)
- Last update posted
- Sep 18, 2014
2009 – 2013
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | La Jolla | California | 92037 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80045 | — |
| Pfizer Investigational Site | Denver | Colorado | 80230 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30309 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60611 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536 | — |
| Pfizer Investigational Site | Portland | Maine | 04102 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48202 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48236 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Rochester | New York | 14642 | — |
| Pfizer Investigational Site | Chapel Hill | North Carolina | 27599 7155 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27705 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267-0589 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45267-0595 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Portland | Oregon | 97239 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29425 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | Charlottesville | Virginia | 22901 | — |
| Pfizer Investigational Site | Charlottesville | Virginia | 22908 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00895583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2014 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00895583 live on ClinicalTrials.gov.